Investors Scene: MYND Life Sciences (CSE:MYND) Introduction

[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]Hey, everyone. Welcome back to Investors Scene, where we bring the insights from the insiders of the companies disrupting the market. And today on the show we introduce you to a newly publicly traded company on the CSE, under the ticker symbol MYND. Now, this company is called Mynd Life Sciences. And it’s a biotech company focused on neuropharmaceutical drug development. Now, the company is advancing psychedelic-derived medicines with an initial focus on major depressive disorder– something that millions upon millions of people are dealing with. Now, the company is also ran by a really, really good team. This isn’t an old mining deal put together with some new IP. MYND is ran by their CEO, who’s a former finance minister of Alberta, currently director of Yorktown Securities, Dr. Lyle Oberg. And of course, with their current research being led by Dr. Wilf Jefferies and his team of PhDs at the University of British Columbia, this team will have the eyeballs of the pharmaceutical industry. In the coming days, we’ll have Dr. Lyle Oberg on the show to tell us more about why Mynd Life Sciences is so different out there. Thanks again for tuning in, and be sure to visit our Investors Scene for more information. And be sure to visit Investors Scene for more information.[/vc_column_text][/vc_column][/vc_row]

Related Articles

Back to top button